Reviews/Ssris and Snris/SSRIs increase suicidal ideation in children and adolescents
· SS-SAF-03 · v2
This corpus was filtered to primary studies, and within that set only one study directly measured suicidal thoughts in young people taking SSRIs; it found no lasting rise, with a brief excess only around the day the drug was first prescribed [13]. Two large real-world studies looked at suicide attempts rather than thoughts and found no increase, or a reduction, after young people started an SSRI [8],[11]. Comparisons between different antidepressants and population-level prescribing data pointed the same neutral or opposite way [19],[10]. The studies that most clearly report an increase in suicidal thinking were pooled trial summaries [1],[9], and these were set aside by the rule that keeps only primary studies. The panel therefore judged the claim unsupported by the evidence that remained, while noting openly that this result depends on that filtering choice.
Within the included primary corpus, the direct ideation signal comes from a single self-controlled study [13], which reports no sustained increase in suicide-related events and an excess only on the day of prescription. The two large cohorts measure suicidal behaviour or attempts, not ideation, and find a reduced within-individual risk after SSRI initiation (IRR = 0.62) [8] and no statistically significant increase in attempts (HR 1.59, CI 0.89-2.82) [11]. Head-to-head comparison of agents found no meaningful differences between SSRIs [19], and an ecological analysis found SSRI prescribing inversely associated with youth suicide [10]. The only quantified increases in suicidal ideation sit in the two meta-analyses [1] (risk ratio 3.51, 95% CI 1.51-8.16) and [9] (RR 1.80, 95% CI 1.19 to 2.72), both excluded by the study-type filter. The contested point: The evidence divides on study type: the excluded pooled-trial summaries [1],[9] report an increase in suicidal ideation, while every included primary study is neutral or points the other way [13],[8],[11],[19],[10]. The panel was explicit that scoring only the included primary corpus produces a result that diverges from the regulatory consensus precisely because the confirmatory meta-analyses were filtered out.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Outcome indirectness: the claim is about suicidal IDEATION, but only [13] among included primary studies measures ideation, and it finds no sustained increase. [8] and [11] measure suicidal behaviour/attempts, not ideation.
The only quantified evidence of increased ideation with SSRIs in youth ([1] RR 3.51; [9] RR 1.80) was removed by the study-type filter. The claim is scored on a corpus from which its strongest confirmatory evidence has been excluded, so a low score reflects filter structure, not necessarily the underlying science.
Where it remains uncertain. The only quantified increases in ideation — [1] RR 3.51 and [9] RR 1.80 — are meta-analyses removed by the study-type filter.
Aleatory
The day-of-prescription signal in [13] rests on 5 and 2 events with very wide confidence intervals (4.5 to 403.4 and 1.1 to 115.6).
Epistemic
The meta-analyses quantifying increased ideation [1],[9] were removed by the study-type filter, so the included corpus omits its strongest confirmatory evidence.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large within-individual cohort contradicting an increase in suicidal behaviour in youths.
“The results do not suggest that SSRI-treatment increases the risk for suicidal behaviour in either youths or adults; rather, it may reduce the risk.”
Panel auditInternal validity: medium · scope of inference: Individuals aged 6-59 (including youths) initiating SSRIs; suicide attempts and deaths.Key limitations: behaviour not ideation outcome · observational confounding by indication · age groups pooled in headline
Ecological inverse association (less SSRI use, more suicide); indirect, points away from the claim.
“the youth suicide rate increased by 49% between 2003 and 2005 and shows a significant inverse association with SSRI prescriptions”
Panel auditInternal validity: low · scope of inference: Population-level SSRI prescribing and suicide rates in under-19s in the US and Netherlands.Key limitations: ecological design · completed suicide not ideation · confounded time trends
Adolescent cohort: no statistically significant increase in suicide attempts (outcome is attempts, not ideation).
Panel auditInternal validity: medium · scope of inference: US managed-care adolescents aged 12-18 newly diagnosed with MDD; coded suicide attempts.Key limitations: attempts not ideation · claims-based ascertainment · confounding by indication
The abstract reports genotype-event associations and explicitly lacks a placebo condition, so no SSRI-versus-control direction can be read.
Panel auditInternal validity: low · scope of inference: Treatment-resistant depressed adolescents genotyped for candidate SNPs associated with suicidal events.Key limitations: no placebo arm · few events · pharmacogenetic focus
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
On the included primary observational corpus the claim is not supported and is partly contradicted, so confidence is low; the verdict is explicitly filter-dependent and diverges from the regulatory consensus because the confirmatory meta-analyses are excluded.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No placebo-controlled ideation trial in the included corpus. The exact outcome and the strongest design are both absent, leaving the direct causal question unanswerable from the primary studies here. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled randomised trial in children and adolescents with prospectively scored suicidal ideation as a pre-specified outcome.
Open question: Does SSRI treatment increase directly measured suicidal ideation in children and adolescents under a placebo-controlled design? Why it is still open: No included primary study tests SSRI versus placebo on ideation; [7] lacks a placebo and [19] has no untreated comparator.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19